Literature DB >> 34716780

Pre-treatment MRI tumor features and post-treatment mammographic findings: may they contribute to refining the prediction of pathologic complete response in post-neoadjuvant breast cancer patients with radiologic complete response on MRI?

Bruna M Thompson1, Luciano F Chala2, Carlos Shimizu1,2, Max S Mano3, José R Filassi4, Felipe C Geyer5, Ulysses S Torres6, Giselle Guedes Netto de Mello2, Cláudia da Costa Leite1.   

Abstract

PURPOSE: Radiologic complete response (rCR) in breast cancer patients after neoadjuvant chemotherapy (NAC) does not necessarily correlate with pathologic complete response (pCR), a marker traditionally associated with better outcomes. We sought to verify if data extracted from two important steps of the imaging workup (tumor features at pre-treatment MRI and post-treatment mammographic findings) might assist in refining the prediction of pCR in post-NAC patients showing rCR.
METHODS: A total of 115 post-NAC women with rCR on MRI (2010-2016) were retrospectively assessed. Pre-treatment MRI (lesion morphology, size, and distribution) and post-treatment mammographic findings (calcification, asymmetry, mass, architectural distortion) were assessed, as well as clinical and molecular variables. Bivariate and multivariate analyses evaluated correlation between such variables and pCR. Post-NAC mammographic findings and their correlation with ductal in situ carcinoma (DCIS) were evaluated using Pearson's correlation.
RESULTS: Tumor distribution at pre-treatment MRI was the only significant predictive imaging feature on multivariate analysis, with multicentric lesions having lower odds of pCR (p = 0.035). There was no significant association between tumor size and morphology with pCR. Mammographic residual calcifications were associated with DCIS (p = 0.009). The receptor subtype remained as a significant predictor, with HR-HER2 + and triple-negative status demonstrating higher odds of pCR on multivariate analyses.
CONCLUSIONS: Multicentric lesions on pre-NAC MRI were associated with a lower chance of pCR in post-NAC rCR patients. The receptor subtype remained a reliable predictor of pCR. Residual mammographic calcifications correlated with higher odds of malignancy, making the correlation between mammography and MRI essential for surgical planning. Key Points • The presence of a multicentric lesion on pre-NAC MRI, even though the patient reaches a radiologic complete response on MRI, is associated with a lower chance of pCR. • Molecular status of the tumor remained the only significant predictor of pathologic complete response in such patients in the present study. • Post-neoadjuvant residual calcifications found on mammography were related to higher odds of residual malignancy, making the correlation between mammography and MRI essential for surgical planning.
© 2021. European Society of Radiology.

Entities:  

Keywords:  Breast cancer; Magnetic resonance imaging; Mammography; Pathologic complete response; Radiologic complete response

Mesh:

Year:  2021        PMID: 34716780     DOI: 10.1007/s00330-021-08290-1

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   7.034


  29 in total

1.  Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.

Authors:  Jennifer F De Los Santos; Alan Cantor; Keith D Amos; Andres Forero; Mehra Golshan; Janet K Horton; Clifford A Hudis; Nola M Hylton; Kandace McGuire; Funda Meric-Bernstam; Ingrid M Meszoely; Rita Nanda; E Shelley Hwang
Journal:  Cancer       Date:  2013-02-21       Impact factor: 6.860

2.  Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?

Authors:  B Schaefgen; M Mati; H P Sinn; M Golatta; A Stieber; G Rauch; A Hennigs; H Richter; C Domschke; F Schuetz; C Sohn; A Schneeweiss; Joerg Heil
Journal:  Ann Surg Oncol       Date:  2015-10-14       Impact factor: 5.344

Review 3.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Authors:  Patricia Cortazar; Lijun Zhang; Michael Untch; Keyur Mehta; Joseph P Costantino; Norman Wolmark; Hervé Bonnefoi; David Cameron; Luca Gianni; Pinuccia Valagussa; Sandra M Swain; Tatiana Prowell; Sibylle Loibl; D Lawrence Wickerham; Jan Bogaerts; Jose Baselga; Charles Perou; Gideon Blumenthal; Jens Blohmer; Eleftherios P Mamounas; Jonas Bergh; Vladimir Semiglazov; Robert Justice; Holger Eidtmann; Soonmyung Paik; Martine Piccart; Rajeshwari Sridhara; Peter A Fasching; Leen Slaets; Shenghui Tang; Bernd Gerber; Charles E Geyer; Richard Pazdur; Nina Ditsch; Priya Rastogi; Wolfgang Eiermann; Gunter von Minckwitz
Journal:  Lancet       Date:  2014-02-14       Impact factor: 79.321

4.  MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy.

Authors:  Mette S van Ramshorst; Claudette E Loo; Emilie J Groen; Gonneke H Winter-Warnars; Jelle Wesseling; Frederieke van Duijnhoven; Marie-Jeanne T Vrancken Peeters; Gabe S Sonke
Journal:  Breast Cancer Res Treat       Date:  2017-04-21       Impact factor: 4.872

5.  Breast radiologic complete response is associated with favorable survival outcomes after neoadjuvant chemotherapy in breast cancer.

Authors:  Jinsun Woo; Jai Min Ryu; Sung Mi Jung; Hee Jun Choi; Se Kyung Lee; Jonghan Yu; Jeong Eon Lee; Seok Won Kim; Seok Jin Nam; Byung Joo Chae
Journal:  Eur J Surg Oncol       Date:  2020-09-14       Impact factor: 4.424

6.  Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).

Authors:  A Schneeweiss; S Chia; T Hickish; V Harvey; A Eniu; R Hegg; C Tausch; J H Seo; Y-F Tsai; J Ratnayake; V McNally; G Ross; J Cortés
Journal:  Ann Oncol       Date:  2013-05-22       Impact factor: 32.976

7.  Reoperation rates after breast conserving surgery for breast cancer among women in England: retrospective study of hospital episode statistics.

Authors:  R Jeevan; D A Cromwell; M Trivella; G Lawrence; O Kearins; J Pereira; C Sheppard; C M Caddy; J H P van der Meulen
Journal:  BMJ       Date:  2012-07-12

8.  Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis.

Authors:  Michael L Marinovich; Petra Macaskill; Les Irwig; Francesco Sardanelli; Eleftherios Mamounas; Gunter von Minckwitz; Valentina Guarneri; Savannah C Partridge; Frances C Wright; Jae Hyuck Choi; Madhumita Bhattacharyya; Laura Martincich; Eren Yeh; Viviana Londero; Nehmat Houssami
Journal:  BMC Cancer       Date:  2015-10-08       Impact factor: 4.430

9.  Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.

Authors:  Xiao-song Chen; Ying Yuan; David H Garfield; Jia-yi Wu; Ou Huang; Kun-wei Shen
Journal:  PLoS One       Date:  2014-09-23       Impact factor: 3.240

10.  Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).

Authors:  Simon Peter Gampenrieder; Andreas Peer; Christian Weismann; Matthias Meissnitzer; Gabriel Rinnerthaler; Johanna Webhofer; Theresa Westphal; Marina Riedmann; Thomas Meissnitzer; Heike Egger; Frederike Klaassen Federspiel; Roland Reitsamer; Cornelia Hauser-Kronberger; Katharina Stering; Klaus Hergan; Brigitte Mlineritsch; Richard Greil
Journal:  Breast Cancer Res       Date:  2019-01-31       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.